Why the study?
Massive pleural effusion in SARS-CoV-2 infection is rare, highlighting the need for diagnostic laboratory modalities to determine etiology and effective treatment.
ADA analysis can be a useful initial diagnostic tool for determining the etiology of massive pleural effusion, such as tuberculous pleurisy, in patients with concurrent COVID-19 infection.
Answers are grounded in this paper and cite their sources.
SARS-CoV-2 in pleural exudate; leaves open diagnostic role of fluid analysis in young patients with effusion.
A 26-year-old man complained of shortness of breath for 3 days before the hospital admission. The patient had a history of coughing up blood and had consumed alcohol and drugs. Decreased vesicular auscultation and dull percussion in the left lateral pulmo. Laboratory result showed increased neutrophil-lymphocyte ratio C-reactive protein, D-dimer, procalcitonin, ferritin, and decreased albumin level. Pleural fluid analysis indicated the presence of exudate, SARS-CoV-2 PCR positive, and increased ADA level to 43 U/L. Based on the examination results, we suspected that the etiology of the massive pleural effusion was tuberculous pleurisy, particularly due to increased ADA levels. The patient was diagnosed with COVID-19 pneumonia with massive pleural effusion and tuberculous pleurisy. Massive pleural effusion in SARS-CoV-2 infection is rare. Thus, laboratory modalities for massive pleural effusion diagnosis are needed to determine the etiology and effective treatment for the patient. ADA analysis could be considered as an initial examination in patients with pleural effusion during the wait for pleural fluid culture results.
No takes yet. Share an insight, caveat, or question.
Novianti et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: